We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Lucigen, Epicentre Announces Agreement

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

With this agreement, effective January 1, 2017, select Epicentre products will be manufactured and sold exclusively by Lucigen Corporation directly to customers and through its distribution network worldwide. Epicentre Technologies, known for its genomics and transcriptomics products for gene expression, cloning, and in vitro transcription, was acquired by Illumina in 2011, and continues to operate as a wholly owned subsidiary of Illumina in Madison, Wisconsin.

This select group of products for transposomics, microarray analysis, and transcriptomics complements Lucigen’s portfolio of tools for use in synthetic biology, next generation sequencing, genetic amplification, and protein expression.

The incorporation of products from the Epicentre portfolio broadens Lucigen’s portfolio of genomics tools that accelerate and simplify life science research. Illumina’s agreement with Lucigen reflects good cooperation between the companies in order to continue the delivery and service of these high quality products to life science researchers.

“We are excited to expand and enrich our product offering to serve scientists worldwide with unique tools that will deliver innovative and meaningful breakthroughs in life sciences” stated Ralph Kauten, CEO of Lucigen.

Source: Story from Lucigen. Please note: The content above may have been edited to ensure it is in keeping with Technology Networks' style and length guidelines.